Global Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials Market Research Report 2022 - ResearchAndMarkets.com

The "Wet (Neovascular / Exudative) Macular Degeneration - Global Clinical Trials Review, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Wet (Neovascular / Exudative) Macular Degeneration - Global Clinical Trials Review, 2022 provides an overview of Wet (Neovascular / Exudative) Macular Degeneration Clinical trials scenario.

This report provides top line data relating to the clinical trials on Wet (Neovascular / Exudative) Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Key Topics Covered:

• Report Guidance
• Publisher Clinical Trials Report Coverage
• Clinical Trials by Region
• Clinical Trials and Average Enrollment by Country
• Clinical Trials by G7 Countries: Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials
• Clinical Trials by Phase in G7 Countries
• Clinical Trials in G7 Countries by Trial Status
• Clinical Trials by E7 Countries: Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials
• Clinical Trials by Phase in E7 Countries
• Clinical Trials in E7 Countries by Trial Status
• Clinical Trials by Phase
• In Progress Trials by Phase
• Clinical Trials by Trial Status
• Clinical Trials by End Point Status
• Subjects Recruited Over a Period of Time
• Clinical Trials by Sponsor Type
• Prominent Sponsors
• Top Companies Participating in Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials
• Prominent Drugs
• Clinical Trial Profile Snapshots
• Appendix

Companies Mentioned

• Novartis AG
• Bayer AG
• F. Hoffmann-La Roche Ltd
• Regeneron Pharmaceuticals Inc
• Pfizer Inc
• Alcon Inc
• IVERIC bio Inc
• Chengdu Kanghong Pharmaceuticals Group Co Ltd
• AbbVie Inc
• Syneos Health Inc

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/bt1uka.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005905/en/